Kamada Ltd (KMDA)

Jul 24, 2025

Kamada Ltd. Stock Analysis and ForecastExtraordinary performance - Autocar Professional

Jul 24, 2025

Jul 24, 2025

What drives Kamada Ltd. stock priceSpectacular growth rates - Autocar Professional

Jul 24, 2025

Jul 23, 2025

What analysts say about Kamada Ltd. stockExceptional growth trajectory - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Is Kamada Ltd. a good long term investmentBreakthrough capital growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What makes Kamada Ltd. stock price move sharplyHigh Potential Safe Trades - Newser

Jul 22, 2025

Jul 15, 2025

Why Kamada Ltd. stock attracts strong analyst attentionFree Real-Time Trading Opportunities - Newser

Jul 15, 2025

Jul 15, 2025

How Kamada Ltd. stock performs during market volatilityProfitable Yet Secure Picks - Newser

Jul 15, 2025

Jul 15, 2025

Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights - openPR.com

Jul 15, 2025

Jul 15, 2025

Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - The Globe and Mail

Jul 15, 2025

Jul 15, 2025

Emphysema Pipeline 2025: MOA, ROA, And Clinical Trial Insights Explored By Delveinsight Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - MenaFN

Jul 15, 2025

Jul 04, 2025

Is Kamada (KMDA) Stock Undervalued Right Now? - Nasdaq

Jul 04, 2025

Jun 20, 2025

Kamada confirms continuous business operations despite recent events in Middle East - MSN

Jun 20, 2025

Jun 18, 2025

Should Value Investors Buy Kamada (KMDA) Stock? - Yahoo Finance

Jun 18, 2025

Jun 17, 2025

Kamada Confirms Continuous Global Business Operations and - GlobeNewswire

Jun 17, 2025

Jun 17, 2025

Kamada Ensures Global Operations Amid Middle East Tensions - TipRanks

Jun 17, 2025

Jun 17, 2025

Kamada confirms continuous business operations despite Middle East events - TipRanks

Jun 17, 2025

Jun 17, 2025

Kamada Confirms No Supply Disruptions: How Israeli Biotech Giant Safeguards Global Product Availability - Stock Titan

Jun 17, 2025

Jun 17, 2025

Plasma Therapeutics Market Revenue to Attain USD 46.46 Bn by 2033 - Precedence Research

Jun 17, 2025

Jun 11, 2025

Kamada Reports Strong Q1 2025 Growth with Plasma Business Expansion and Key Milestones - citybuzz -

Jun 11, 2025

Jun 10, 2025

Implied Volatility Surging for Kamada Stock Options - Yahoo Finance

Jun 10, 2025

Jun 07, 2025

Kamada Intensifies Efforts to Highlight CYTOGAM's Role in Combatting CMV in Organ Transplant Patients - citybuzz -

Jun 07, 2025

Jun 06, 2025

Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM - FinancialContent

Jun 06, 2025

Jun 03, 2025

Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA) - Defense World

Jun 03, 2025

Jun 02, 2025

Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance

Jun 02, 2025

May 27, 2025

Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com

May 27, 2025

May 27, 2025

Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World

May 27, 2025

May 23, 2025

Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World

May 23, 2025

May 22, 2025

Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st

May 22, 2025